HomeEXEL • NASDAQ
add
Exelixis Inc
Nakaraang pagsara
$22.56
Sakop ng araw
$22.53 - $22.75
Sakop ng taon
$18.64 - $24.34
Market cap
6.58B USD
Average na Volume
1.50M
P/E ratio
34.95
Dividend yield
-
Primary exchange
NASDAQ
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 425.23M | 4.02% |
Gastos sa pagpapatakbo | 341.67M | -6.56% |
Net na kita | 37.32M | -6.77% |
Net profit margin | 8.78 | -10.32% |
Kita sa bawat share | 0.17 | 6.25% |
EBITDA | 68.68M | 92.45% |
Aktuwal na % ng binabayarang buwis | 24.26% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 963.26M | -26.64% |
Kabuuang asset | 2.80B | -10.80% |
Kabuuang sagutin | 675.74M | 14.88% |
Kabuuang equity | 2.13B | — |
Natitirang share | 291.29M | — |
Presyo para makapag-book | 3.13 | — |
Return on assets | 5.42% | — |
Return on capital | 6.48% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | 37.32M | -6.77% |
Cash mula sa mga operasyon | 68.82M | -18.47% |
Cash mula sa pag-invest | 111.79M | 325.43% |
Cash mula sa financing | -184.05M | -4,113.26% |
Net change in cash | -3.43M | -108.71% |
Malayang cash flow | 44.17M | 15,692.81% |
Tungkol
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
Itinatag
Nob 15, 1994
Headquarters
Website
Mga Empleyado
1,310
